Miscellaneous :

General

This support group serves as an information center for other discussions on health topics.

Join this Group

Group Home Discussions Comments Members FAQs Resources Activities Ask An Expert Find Help

News Comments

Add a topic

Recent discussions

	Start watching this topic
Long-term Apremilast Demonstrates Continued Efficacy in Patients With Psoriatic Arthritis: Research
medindia 8870 Posts New data show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks. The data was presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism. For patients who completed 52 weeks of the study, up to 65% achieved ACR20* response rates. Also, apremilast continued to be well tolerated with an acceptable longer-term safety profile. ...Read More
Posted on : Thursday, June 4, 2015 1:28 PM

Add reply No of replies : 1

Report Abuse

You can help us in removing abusive content or spam.
Your Name
Your Email ID
Subject
Message		(Maximum 3000 Characters)

Epaphras
5 Posts

At the end of week 52 the observation was that patients achieved 63% ACR20 through apremilast 20 mg and 30 mg, then what about the rest 37% and 45.4% ?

Replied on Thursday, June 4, 2015 1:28 PM

Report Abuse

Member Sign In